The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | AI-driven IPN programs enhance lung cancer detection beyond LDCT
Luis Raez, MD, Memorial Cancer Institute, Pembroke Pines, FL, discusses the role of incidental pulmonary nodule (IPN) programs, supported by artificial intelligence (AI), in complementing low-dose CT (LDCT) screening for lung cancer. By integrating automated detection with electronic medical records and specialist review, the program identified more early-stage cases than LDCT alone in a comparable period. This approach expanded access to underserved populations, reduced disparities, and optimized use of healthcare resources. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are doing that. That’s why we’re showing our poster in World Lung. Basically, what we do is we, you know, healthcare system, we work for Memorial Healthcare System. It’s a large healthcare system in Broward County, Miami, Florida. We do 250,000 CAT scans per year in our healthcare system. So there is no way that the nurses or navigators can review all of these CAT scan results...
We are doing that. That’s why we’re showing our poster in World Lung. Basically, what we do is we, you know, healthcare system, we work for Memorial Healthcare System. It’s a large healthcare system in Broward County, Miami, Florida. We do 250,000 CAT scans per year in our healthcare system. So there is no way that the nurses or navigators can review all of these CAT scan results. So we use artificial intelligence to screen these 250,000 reports. And then the artificial intelligence program that we have for Illuminate selects around 4,000 reports that are suspicious because they have nodules and they have large nodules and things like that. Then our navigators start to follow these reports and try to figure out which patients are suspicious that need further workup, meaning to be seen by a pulmonologist, a surgeon, CAT scan, PET scan, biopsy, and which patients know. For example, if you are a 20-year-old with a 3-millimeter nodule, the chance of lung cancer is probably zero. If you are a 60-year-old who’s been smoking with a 1-centimeter nodule, you have a very high chance of needing to go for a workup. So that’s the way that we do. And doing that, implementing that, we have diagnosed in two years around 120 patients with lung cancer, compared with only 20 in the conventional lung screening that we’re waiting for the patients to come to the hospital.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
